Skeletal complications of ADT: Disease burden and treatment options

Asian Journal of Andrology

Volumn 14, Issue 5, 2012, Pages 670-675

  Planas Morin, Jacques ^a   Morote Robles, Juan ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

androgen deprivation therapy; bisphosphonates; bone fracture; bone mass loss; calcium intake; osteoclast; osteoporosis; prostate cancer

Indexed keywords

ALENDRONIC ACID; AROMATASE INHIBITOR; BICALUTAMIDE; CALCIUM; DENOSUMAB; ETIDRONIC ACID; GONADORELIN DERIVATIVE; LEUPRORELIN; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; TOREMIFENE; VITAMIN D; ZOLEDRONIC ACID;

ALCOHOL CONSUMPTION; ANDROGEN DEPRIVATION THERAPY; BONE DENSITOMETRY; BONE DENSITY; BONE MASS; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PATIENT; CLINICAL TRIAL (TOPIC); DIET THERAPY; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; KYPHOSIS; LIFESTYLE MODIFICATION; MALE; ORCHIECTOMY; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANCE TRAINING; RESPIRATORY FAILURE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SMOKING; VERTEBRA FRACTURE;

ANDROGEN ANTAGONISTS; BONE DENSITY; BONE NEOPLASMS; DIPHOSPHONATES; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 84866260143     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2012.70     Document Type: Review

References (42)

1. Jemal A Siegel R Xu J Ward E. Cancer statistics 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Yoneda T Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun 2005; 328: 679-87.
3. [No authors listed.] Medicine 2006; 9 Extr. 1:1-7.
4. Smith MR Malkowicz SB Brawer MK Hancock ML Morton RA et al. Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer. J Urol 2011; 186: 2239-44.
5. Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997; 157: 439-44.
6. Townsend MF Sanders WH Northway RO Graham SD. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 1997; 79: 545-50.
7. Shahinian VB Kuo YF Freeman JL Orihuela E Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 2005; 103: 1615-24.
8. BarryMJ,DelorenzoMA,Walker-Corkery ES,LucasFL,WennbergDC. The risingprevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: A population-based cohort study. BJU Int 2006; 98: 973-8.
9. Kong YY Yoshida H Sarosi I Tan HL Timms E et al. OPGL is a key regulator of osteoclastogenesis lymphocyte development and lymph-node organogenesis. Nature 1999; 397: 315-23.
10. Jiang HX Majumdar SR Dick DA Moreau M Raso J et al. Development and initial validation of a risk score for predicting in-hospital and 1-year mortality in patients with hip fractures. J Bone Miner Res 2005; 20: 494-500.
11. Roche JJ Wenn RT Sahota O Moran CG. Effect of comorbidities and postoperative complications on mortality after hip fracture in elderly people: Prospective observational cohort study. BMJ 2005; 331: 1374.
12. Oefelein MG Richiutti V Conrad W Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002; 168: 1005-7.
13. Morote J Martinez E Trilla E Esquena S Abascal JM et al. Osteoporosis during continuous androgen deprivation: Influence of the modality and length of treatment. Eur Urol 2003; 44: 661-5.
14. Dickman PW Adolfsson J Astrom K Steineck G. Hip fractures in men with prostate cancer treated with orchiectomy. J Urol 2004; 172: 2208-12.
15. Smith MR Lee WC Brandman J Wang Q Botteman M et al. Gonadotropin- releasing hormone agonists and fracture risk: A claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005; 23: 7897-903.
16. Shahinian VB Kuo YF Freeman JL Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154-64.
17. Assesment of fracture risk andits application to screening forpostmenopausal osteoporosis. Report of a WHO Study Group.World Health Organ Tech Rep Ser 1994; 843: 1-129.
18. Morote J Planas J Mir MC Raventos CX Encabo G et al. 33% radius evaluation to assess bone mineral density in prostate cancer patients. World J Urol 2010; 29: 815-9.
19. Saylor PJ Kaufman DS Michaelson MD Lee RJ Smith MR. Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. J Urol 2010; 183: 2200-5.
20. Hussain SA Weston R Stephenson RN George E Parr NJ. Immediate dual energy Xray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation. BJU Int 2003; 92: 690-4.
21. Higano CS. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know? Nat Clin Pract Urol 2008; 5: 24-34.
22. Greenspan SL Coates P Sereika SM Nelson JB Trump DL et al. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 2005; 90: 6410-7.
23. Morote J Orsola A Abascal JM Planas J Trilla E et al. Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression. J Urol 2006; 175: 1679-83; discussion 1683.
24. Morote J Morin JP Orsola A Planas J Trilla E et al. Prevalence of osteoporosis during ongtermandrogendeprivationtherapyinpatientswithprostatecancer. Urology2007;69:500-4.
25. Vogel JM Davis JW Nomura A Wasnich RD Ross PD. The effects of smoking on bone mass and the rates of bone loss among elderly Japanese-American men. J Bone Miner Res 1997; 12: 1495-501.
26. Ross PD. Risk factors for osteoporotic fracture. Endocrinol Metab Clin North Am 1998; 27: 289-301.
27. NIH consensus conference. Optimal calclium intake. JAMA 1994; 272: 1942-8.
28. Planas J Morote J Orsola A Salvador C Trilla E et al. The relationship between daily calcium intake and bone mineral density in men with prostate cancer. BJU Int 2007; 99: 812-5; discussion 815-6.
29. Todd JA Robinson RJ. Osteoporosis and exercise. Postgrad Med J 2003; 79: 320.
30. Higano C Shields A Wood N Brown J Tangen C. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. Urology 2004; 64: 1182-6.
31. Smith MR Goode M Zietman AL McGovern FJ Lee H et al. Bic alutamide monotherapy versus leuprolide monotherapy for prostate cancer: Effects on bone mineral density and body composition. J Clin Oncol 2004; 22: 2546-53.
32. Smith MR Morton RA Barnette KG Sieber PR Malkowicz SB et al. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol 2010; 184: 1316-21.
33. Diamond T Campbell J Bryant C Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: Longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 1998; 83: 1561-6.
34. Izumi K Mizokami A Sugimoto K Narimoto K Miwa S et al. Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy. Urology 2009; 73: 1342-6.
35. Smith MR Mc Govern FJ Zietman AL Fallon MA Hayden DL et al. Pamidronate to prevent bone loss inmen receiving gonadotropin releasing hormone agonist therapy for prostate cancer. N Engl J Med 2001; 345: 948-55.
36. Smith MR Eastham J Gleason DM Shasha D Tchekmedyian S et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169: 2008-12.
37. Michaelson MD Kaufman DS Lee H McGovern FJ Kantoff PW et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007; 25: 1038-42.
38. Greenspan SL Nelson JB Trump DL Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: A randomized trial. Ann Intern Med 2007; 146: 416-24.
39. SmithMR Egerdie B Hernandez Toriz N Feldman R Tammela TL et al. Denosumab inmen receivingandrogen-deprivation therapy forprostatecancer.NEnglJMed 2009;361:745-55.
40. Falahati-Nini A Riggs BL Atkinson EJ O'Fallon WM Eastell R et al. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 2000; 106: 1553-60.
41. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington DC: National Osteoporosis Foundation; 2010.
42. Heidenreich A Bastian PJ Bellmunt J Bolla M Joniau S et al. Guidelines on prostate cancer 2010. Available from: http://uroweb.org/guidelines/online- guidelines/